Cargando…
ANGI-1 ASSESSING THE THERAPEUTIC EFFECT OF BEVACIZUMAB USING FMISO-PET IN GBM THERAPY
BACKGROUND: Gd-enhanced MRI and T2WI/FLAIR images are used to determine the efficacy of bevacizumab(Bev) in glioblastoma(GBM). FMISO-PET reflects hypoxia in tumor tissue. In this study, we hypothesized that FMISO-PET could detect a series of changes in the hypoxic environment during the Bev effect a...
Autores principales: | Suzuki, Tomoya, Tanaka, Toshihide, Takei, Jun, Miyake, Keisuke, Suzuki, Kenta, Ogawa, Daisuke, Akasaki, Yasuharu, Yuichi, Murayama |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719327/ http://dx.doi.org/10.1093/noajnl/vdac167.000 |
Ejemplares similares
-
ANGI-1 Impact of neoadjuvant bevacizumab on transcriptional factor for stemness, macrophage polarization, and oxygenation of tumor microenvironment in glioblastoma
por: Tanaka, Toshihide, et al.
Publicado: (2021) -
ANGI-01 ALTERATION IN IMMUNE REGULATORY CELLS BEFORE AND AFTER TREATMENT BY STUPP REGIMEN WITH OR WITHOUT BEVACIZUMAB FOR GLIOBLASTOMA
por: Tanaka, Toshihide, et al.
Publicado: (2019) -
“Paradoxical” findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab
por: Yamamoto, Yohei, et al.
Publicado: (2017) -
Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p/19q codeletion status in newly diagnosed malignant gliomas
por: Suzuki, Kenta, et al.
Publicado: (2021) -
Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab
por: Tamura, Ryota, et al.
Publicado: (2018)